Syndromic agammaglobulinemia
MONDO:0016463A agammaglobulinemia that is part of a larger syndrome.
Also known as: hypogammaglobulinemia, syndrome associated with agammaglobulinemia, syndromic agammaglobulinemia, syndromic hypogammaglobulinemia
74 clinical trials for this condition and its sub-types, 7 tagged with Syndromic agammaglobulinemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Syndromic agammaglobulinemia
-
Common variable immunodeficiency 29 trials · 31 incl. sub-types
16 sub-types
- Immunodeficiency, common variable, 12 1 trial
- Pancytopenia due to IKZF1 mutations 1 trial
- IL21-related infantile inflammatory bowel disease 0 trials
- Combined immunodeficiency due to LRBA deficiency 0 trials
- Immune deficiency, familial variable 0 trials
- Immunodeficiency, common variable, 1 0 trials
- Immunodeficiency, common variable, 10 0 trials Sub-types →
- Immunodeficiency, common variable, 14 0 trials
- Immunodeficiency, common variable, 15 0 trials
- Immunodeficiency, common variable, 2 0 trials
- Immunodeficiency, common variable, 3 0 trials
- Immunodeficiency, common variable, 4 0 trials
- Immunodeficiency, common variable, 5 0 trials
- Immunodeficiency, common variable, 6 0 trials
- Immunodeficiency, common variable, 7 0 trials
- Immunodeficiency, common variable, due to APRIL deficiency 0 trials
-
Transient hypogammaglobulinemia 0 trials
1 sub-type
Most studied deeper sub-types
-
Can a simple antibody infusion shield myeloma patients from infections?
Disease control Recruiting nowThis study tests whether IgPro20 (HIZENTRA), a concentrated antibody solution given under the skin, can prevent infections in people with multiple myeloma who have low antibody levels due to bispecific antibody therapy. About 100 participants will either receive IgPro20 plus stan…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug aims to shield autoimmune patients from Life-Threatening infections
Disease control Recruiting nowThis study tests whether a medicine called Panzyga can prevent major infections in people with autoimmune or rheumatic conditions who have low antibody levels after receiving B-cell depletion therapy. About 360 adults will receive either Panzyga or a placebo, and researchers will…
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for blood cancer patients: drug aims to slash infection risk
Disease control Recruiting nowThis study tests whether a medicine called XEMBIFY, given every two weeks alongside standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody lev…
Phase 3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Fatigue in MS might be caused by low antibodies – new study investigates
Knowledge-focused Recruiting nowThis study looks at whether low levels of immunoglobulin G (IgG), a type of antibody, are linked to fatigue in people with multiple sclerosis (MS). Researchers will compare fatigue scores and infection rates between MS patients with low IgG and those with normal IgG. The goal is …
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC